3D Structural Imaging of Human Breast Tissues

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06454214

Enrollment

100

Registered

2024-06-12

Start date

2024-07-01

Completion date

2027-06-04

Last updated

2024-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Human Breast Tissues

Keywords

breast tumor, tumor assessment, tumor microenvironment, digital pathology, 3D pathology

Brief summary

This project aims to develop an advanced ex vivo medical microscopic imaging technology. By developing breast tissue staining techniques, acquiring microscopic images, and performing structural reconstruction, we seek to observe the 3D structure of breast tissue. This includes examining cell distribution, mammary ducts, and blood vessel distribution, to explore the different biological characteristics between normal breast tissue and various types of cancerous tissues.

Interventions

DEVICEMulti-photon microscopy

To conduct 3D structural imaging on human breast tissues

Study design

Observational model

CASE_ONLY

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adults aged 18 and above. * Patients clinically diagnosed with breast cancer.

Exclusion criteria

* Patients unable to provide consent (e.g., inability to speak, inability to communicate in Chinese, etc.). * Patients for whom a definitive pathological diagnosis cannot be established. * Patients suitable only for biopsy and not for surgical excision. * Excised tissue showing severe radiation-induced changes under pathological examination. * Tumor specimens smaller than 1 cm. * Patients with ductal carcinoma in situ (DCIS).

Design outcomes

Primary

Measure	Time frame	Description
Accuracy dependency on staining dye selection	3 years	Using other types of staining agents, compare the diagnostic accuracy of the results with those of traditional pathological staining agents.

Secondary

Measure	Time frame	Description
Comparison between 3D pathology vs. FFPE on breast cancer samples with a focus on image contrast	3 years	Verify whether the contrast and other conditions can provide pathologists with critical information for interpretation. The images will also be compared with the results observed using traditional pathology methods.

Contacts

Primary ContactMing-Yang Wang, PhD

A00581@ntucc.gov.tw+886-23123456

Backup ContactYao-Chen Tseng, Master

opiuy1234567@yahoo.com.tw+886-33661552

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026